Pharmaceutical Benefits Advisory Committee (PBAC)

Company

Last mentioned: Feb 27, 2026

Timeline

  1. Public Advocacy Surge

    Increased media coverage and patient advocacy highlight the pricing disparity between genders.

  2. TGA Approval

    The Therapeutic Goods Administration approves the first female-specific testosterone cream.

  3. Global Consensus Statement

    International medical societies reach consensus on testosterone use for women's sexual health.

Stories mentioning Pharmaceutical Benefits Advisory Committee (PBAC) 1

Health Policy Neutral

Australia's Testosterone Gender Gap: Women Face Higher Costs for Vital Therapy

Australian women are facing significant financial barriers to accessing testosterone therapy, often paying substantially more than men for the same hormone treatment. While the therapy is clinically recognized for treating sexual dysfunction in postmenopausal women, the lack of subsidized options highlights a systemic gap in the national pharmaceutical framework.

2 sources

About Pharmaceutical Benefits Advisory Committee (PBAC) coverage

This page surfaces every story mentioning Pharmaceutical Benefits Advisory Committee (PBAC) across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.

Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.

What you seeWhat it tells you
Story countNumber of distinct stories where Pharmaceutical Benefits Advisory Committee (PBAC) was a primary or referenced actor.
Recency clusteringWhether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc).
Sentiment distributionAggregate sentiment of the stories mentioning this entity, weighted by impact score.
Cross-niche linksWhen the same entity surfaces in our sibling networks, we link to those views to enrich context.